Background: Regulatory T cells (Tregs) are a cornerstone of graft acceptance. High numbers of Tregs are associated with better long-term graft survival. Recently, Vitamin D was suggested as an immunomodulator, in addition to its classical role in calcium metabolism. Vitamin D modulates Tregs and might, thereby, promote graft acceptance and long-term graft survival. Methods: One hundred twenty-three renal allograft recipients attending either Heidelberg nephrology or Giessen internal medicine clinic were enrolled in this cross-sectional study. Sixteen healthy controls were studied in addition. Sixty-nine patients were receiving no vitamin D, 38 calcitriol, and 16 cholecalciferol supplementations. We evaluated whether there was a difference in the absolute numbers of Helios
, and total Tregs were similar in the cholecalciferol and healthy control groups (p = NS). Conclusion: Our findings indicate that cholecalciferol, even when administered at low dosages, has a stabilizing effect on Tregs (particularly the Helios + subset), in contrast to calcitriol which showed neither a stabilizing nor a proliferation-inducing effect on the same cell population.
Keywords: Treg, Cholecalciferol, Calcitriol, Renal transplantation Background T regulatory cells (Tregs) represent a subset of professional cells with powerful immunosuppressive activity. They modulate the immune responses, abrogate autoimmune diseases, and maintain self-tolerance. High numbers of Tregs in peripheral blood of renal transplant recipients were shown to be associated with long-term renal graft survival [1] . Generally, Tregs express the surface markers CD4 + CD25 + Foxp3 + CD127 low/-and can be divided into three distinct subtypes according to their origin: Thymus-derived Tregs (tTregs), peripherally induced Tregs (pTregs), and in vitro-induced Tregs (iTregs) [2] . tTregs originate in the thymus and usually express Helios; a member of the Ikaros family transcription factor. pTregs are induced in the periphery upon exposure to antigens in the absence of inflammatory cytokines. pTregs are antigen specific, express unstable Foxp3, and are often Helios negative [3] [4] [5] . The exact function of Helios remains unclear, however, Getnet et al. showed that Helios enhanced Foxp3 expression [6] [7] . Zabransky et al. reported that the in vitro suppressive function of Tregs correlated with the absolute numbers of Helios + cells. [8] Accordingly, it seems likely that Helios + Tregs represent a highly suppressive Treg subset. Recently, a new Treg subset, Interferongamma producing Tregs (IFNg + Tregs), was discovered in mice and humans [9, 10] . These cells represent the first line of Tregs and exert a suppressive effect on an initial immune response. They include tTregs as well as pTregs [11] . Among many other surface receptors, Tregs express cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which is involved in cell-cell inhibition. Accordingly, CTLA-4 maintains the suppressive capacity of Tregs in animal models [12] .
Beyond its role in calcium homeostasis, vitamin D plays an important role as an immunomodulator. Through the interaction of vitamin D with its intracellular receptor (VDR), and subsequently with the vitamin A/ vitamin A receptor complex, it enters the nucleus, binds to the vitamin D response elements (VDRE) of the promoter regions of different genes, and ultimately modifies the transcription of more than 900 genes [13] . Thereby, vitamin D can affect, either directly or indirectly, about 3 % of the human genome [14] [15] [16] . Ardalan et al. showed that when calcitriol was administered to the donor before renal transplantation, and was continued in the recipients thereafter, it led to a significant increase in the number of CD3 + CD4 + CD25 + cells [17] . A complicating finding is that the resulting higher incidence of hypercalcemia renders the administration of large doses of calcitriol potentially toxic. In contrast, cholecalciferol (vitamin D 3 ) is rather safer when administered in large doses [18] . Cholecalciferol, the native form of vitamin D, undergoes two hydroxylations: the first in the liver to 25 (OH) D 3 (calcidiol), and the second in the kidney to form calcitriol. While administration of a weekly large dose of oral cholecalciferol (140,000 IU/month) for 3 months was reported to significantly increase the numbers of peripheral Tregs in vivo in healthy individuals and patients with Type 1 diabetes [19, 20] In vivo studies on effects of cholecalciferol and calcitriol on different subsets of Tregs in renal allograft patients are scarce. The available publications on in vivo and in vitro studies do not explicitly show which vitamin D form was associated with significantly higher numbers of Tregs in renal allograft patients. In the present study, we were interested in investigating whether the administration of either form of vitamin D is associated with a preferential increase in the numbers of certain subsets of Tregs. From a clinical perspective, it is important to determine whether supplementation with one form or the other in the usual doses prescribed for post transplantation calcium homeostasis is superior regarding an achievement of higher numbers and better suppressive capacity of Tregs. To the best of our knowledge, we believe this is the first study to compare the association of two vitamin D forms with the numbers of Helios + , Helios − , and CTLA-4 + Tregs in renal allograft recipients.
Methods

Patients
This cross-sectional study was conducted between April 2014 and July 2015. Blood samples were collected from renal transplant patients attending outpatient clinics at Heidelberg nephrology and Giessen internal medicine departments. All the samples were analyzed by the same operator at the transplantation immunology department of Heidelberg University. The numbers of Helios , and total Tregs were analyzed in 123 renal transplant patients. As an ancillary part, we analyzed retrospectively whether the patients were supplemented with vitamin D forms or not for at least six months before the time of blood sampling for the T cell subpopulation studies. Patients who received post-transplant vitamin D supplementations for shorter than 6 months before blood sampling were excluded from the study. Fifty-four patients were supplemented post transplantation with vitamin D forms, of whom 38 received oral calcitriol and 16 oral cholecalciferol. Sixty-nine patients were not supplemented. The three groups were compared with 16 healthy controls studied in parallel. The healthy controls were lab staff members who were not suffering from any acute infections or chronic diseases, and were not taking any medications. The patients were reasonably matched regarding gender, age, and follow up time post renal transplantation (P = NS), however, they differed from the healthy controls regarding gender and age ( Calcimagon®, or Vigantoletten®) was prescribed in a onceweekly dose in 70 %, and on a daily basis in 30 % of the cases. The average prescribed dosages are shown in Table 1 .
Determination of PBL subsets
PBL subsets were determined as described previously [24, 25] . For analysis of cell surface determinants, PBL were incubated with fluorochrome-labelled monoclonal antibodies against CD4 (clone RPA-T4), CD25 (clone M -A251), CD127 (clone HIL-7R-M21) (all from BD Biosciences). Intracellular determinants were stained with fluorochrome-labelled monoclonal antibodies against Foxp3 (clone 236A/E7), IFNg (clone B27), CD152 (BN13) and Helios (clone 22 F6) (all BD Biosciences). Briefly, PBL were incubated with combinations of monoclonal antibodies for 30 min and eight-color fluorescence was analyzed using a FACSCanto II triple-laser flow cytometer (BD Biosciences) [24, 25] . When, in addition, intracellular proteins were studied, cell membranes were permeabilized using BD Perm/Wash buffer (BD Biosciences). At least 100,000 events were analyzed in the initial FSC/SSC dot plot.
Statistical analysis
Data are presented as median + interquartile range or percentages. Kruskal-Wallis, Fisher's exact, and Spearman's rank tests were applied. Bonferroni correction for multiple comparisons was performed when indicated. Fig. 1 ). We conclude that (Tables 1 and 2 ). It appears that Helios + as well as Helios − Treg absolute counts were reduced in calcitriol and non-vitamin D patients but were stable in patients supplemented with cholecalciferol. Moreover, the reduction of Helios + Treg appeared to be stronger than the reduction of Helios − Treg. (Tables 1 and 2 ). All immunosuppressed patients had extremely low B-lymphocyte counts.
Results
Higher-dose calcitriol supplementation
We also analyzed whether higher doses of calcitriol (daily doses ≥ 0.5 μg) were associated with higher num (Table 3) . Forty-two percent of the transplanted patients in the calcitriol arm received relatively high doses of calcitriol supplementation at an average weekly dose of 3.5 μg (3.5-7 μg). This higher-dose calcitriol group was similar to the cholecalciferol and control groups regarding age, sex, follow up time post transplantation, the percentage that received anti-thymocyte globulin induction, and maintenance immunosuppressive protocols (p = NS) (Data not shown). ). We observed a moderate correlation in the cholecalciferol group (r = 0.670, p = 0.003), and the calcitriol group (r = 0.470, p = 0.001), and a weak correlation in the non-vitamin D group (r = 0.301, p =0.012). The maximum correlation was observed in healthy controls (r = 0.776, p < 0.001).
Serum creatinine
There was no significant difference in serum creatinine (mg/dl) among the patient groups (p = 0.155).
Discussion
In this retrospective study of renal allograft recipients, we tested a possible association between vitamin D supplementation with either cholecalciferol or calcitriol and the numbers of Tregs. We found that supplementation with cholecalciferol was associated with higher absolute numbers of Helios + Tregs (CD4 We assessed absolute number of cells/μl in addition to the ratio of Tregs to CD4 + and CD8 + cells. Liu et al. demonstrated that the absolute numbers of Tregs, rather than the ratios of Tregs to peripheral lymphocytes, was associated with long-term survival of renal allografts [26] .
Interestingly, as shown in Table 1 , in our study cholecalciferol at an average dose of 7000 IU weekly was associated with higher numbers of Helios + and total Tregs than calcitriol at an average dose of 1.75 μg weekly. In vivo trials reported cholecalciferol supplementation at doses of 140,000 IU monthly or 20,000 IU daily, and 0.5 μg of daily calcitriol in another study [17, 20, 21, 27] . The average dose of cholecalciferol supplemented in our study was thus about 5-20 times lower than the dosages prescribed in these trials, whereas the average dose of calcitriol was about 3 times lower than that administered in a trial conducted by Ardalan et al. [17] . Our results show that cholecalciferol has an effect on Tregs in transplant patients even at relatively low doses.
Although calcitriol can directly affect T cells in vitro, the required doses are much higher than the physiological doses as demonstrated in many studies [16, [28] [29] [30] [31] . In addition, it was demonstrated in healthy persons as well as uremic patients that the bioavailability of 1, 25(OH) 2 D 3 was 70 % of the supplemented dose of oral calcitriol [32] .
De Sévaux et al. showed that calcitriol supplementation in a daily dose of 0.25 μg did not improve the serum 25(OH) D 3 level in renal transplant patients [33] . Consistent with this finding, Marcen et al. demonstrated that calcitriol in a daily dose of 0.25-0.5 μg failed to improve vitamin D deficiency in a cohort of renal transplant patients [34] . In contrast, low dose oral cholecalciferol in a weekly dose of 5000 IU for 15 weeks increased serum 25(OH) D 3 from 18.4 ± 8.2 to 68.6 ± 17.7 nmol/l in a cohort of 34 hemodialysis patients without causing any episode of hypercalcemia [35] . Moreover, oral cholecalciferol showed good long-term 25(OH) D 3 and 1, 25 (OH) 2 D 3 bioavailability, even after 3 months of supplementation with a single dose of 600,000 IU, with a maximal effect at one month [36] . Based on these findings, we speculate that the calcitriol doses supplemented in our study were much lower than the doses required for induction of Tregs in patients, in contrast to cholecalciferol, which can improve vitamin D deficiency even at low doses.
Our study challenges the findings of Ardalan et al., who reported that calcitriol administered to donors 5 days before transplantation at a dose of 0.5 μg and continued at the same dose in the recipients for 1 month after transplantation and thereafter at a dose of 0.25 μg for another 5 months, was associated with a significant increase in the numbers of CD4 + CD25 + cells [17] . This finding is surprising since the doses administered seem too low for the induction of a significant increase of Tregs in the light of other studies. The most likely explanation of To test whether the higher doses of calcitriol administered in Ardalan's study were responsible for the increase in the numbers of Tregs, we compared the patients who were supplemented with comparable or higher doses of calcitriol as the patients in Ardalan's trial with the other two groups of transplanted patients in our study. The higher-dose calcitriol group received an average dose of 3.5 μg weekly. We found that the Tregs were still about two-folds higher in the cholecalciferol arm. This finding suggests that cholecalciferol is superior to calcitriol even when the latter is prescribed at higher doses.
Although [22] .
To find out whether the increase in Treg subset numbers associated with cholecalciferol supplementation was real, we compared cholecalciferol patients with healthy controls. Interestingly, both cholecalciferol groups showed similar Treg subset numbers, whereas calcitriol and no vitamin D supplementation groups showed lower Treg numbers. Accordingly, it appears that cholecalciferol has a stabilizing effect on Treg (particularly Helios + subset) rather than a proliferation-inducing one.
CTLA-4 is a marker associated with the suppressive capacity of Tregs. Cholecalciferol was associated with significantly higher numbers of these cells in comparison to calcitriol and there was a trend of higher numbers also in the no vitamin D supplementation group, whereas the numbers were comparable to healthy controls. We tested the correlation between CTLA- Immunosuppressive drugs have variable effects on Tregs. Cyclosporine has long been known to inhibit the activation of T cells through suppression of calcium-dependent phosphatase calcineurin leading to suppression of IL-2 synthesis. Melony et al. showed that calcineurin inhibitors (CNI) led to expansion of the Treg population in lung allograft recipients [42] . Intriguingly, Ruppert et al. showed that Tregs resisted apoptosis caused by cyclosporine through expression of CD44 [43] . Kogina et al. reported that tacrolimus suppressed T cell receptor-mediated cell division of conventional T cells (CD4 + T cells), whereas it enhanced division of Tregs in vitro [44] . In contrast, other studies showed a harmful effect of CNI on Tregs [45, 46] . In our study, it is unlikely that calcineurin inhibitors were the cause of the increased Treg numbers in the cholecalciferol group as we found no significant difference in CNI prescription among the three patient groups. Mycophenolic acid is one of the most widely used drugs in solid organ transplantation. It exerts its function through inhibition of inosine monophosphate dehydrogenase leading ultimately to B and T cell suppression. Recently, Scotta et al. showed that administration of methylprednisolone, tacrolimus and mycophenolic acid suppressed the viability and proliferation of Tregs. They have also showed that in vivo administration of sirolimus; an inhibitor of the mechanistic target of rapamycin, maintained proliferation and survival of adoptively transferred Tregs [47] . A recent in vitro study published by our group showed variable effects of the immunosuppressive agents on IFNg + and total Tregs [48] .
Conclusions
It appears that cholecalciferol prevents the decrease of Treg commonly observed after transplantation and believed to be a consequence of immunosuppression. Since approximately 51 % of transplant recipients have a vitamin D insufficiency and about 29 % have moderate to severe vitamin D deficiency and patients with low dose cholecalciferol supplementation rarely develop hypercalcemia [49] , the majority of transplant recipients should be supplemented with cholecalciferol. Further clinical studies will be necessary to validate our hypothesis and conclusion.
Since our study is cross-sectional, we can only infer an association between cholecalciferol and increased numbers of Helios + , CTLA-4 + , and total Tregs rather than causality. To prove causality, a randomized prospective study should be conducted. Most of the renal transplant patients in the centers from which the patients were recruited are managed with calcitriol supplementation rather than cholecalciferol. Therefore, we could not enroll more patients into the latter group.
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